All News

Found 59,123 articles

• Coronavirus (COVID-19) Update: FDA Coordinates National Effort to Develop Blood-Related Therapies for COVID-19

  4/3/2020

  The U.S. Food and Drug Administration continues to play a critical role in accelerating medical countermeasures to treat and prevent COVID-19

• Impact of COVID-19 on Medical Devices & Diagnostics Markets: Forecasts & Recovery Timelines Released by LSI & HRI

  4/3/2020

  Medical Devices & Diagnostics (MD&D) companies know they are being impacted by the current pandemic and are seeking independent research to quantify how much their markets will decline or increase, how long the recovery will take, and what factors will determine that recovery.

• BioSig to Host Telebriefing on Development Updates Regarding Vicromax(tm), a Novel Broad-Spectrum Anti-Viral Candidate That May Treat COVID-19

  4/3/2020

  BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform, today announced that it intends to provide a public business update via teleconference regarding its recently acquired anti-viral pharmaceutical candidate, Vicromax(tm)

• Case Study: Treating COVID-19 in a Patient with Multiple Myeloma

  4/3/2020

  A case study of a patient in Wuhan, China, suggests that the immunosuppressant tocilizumab may be an effective COVID-19 treatment for very ill patients who also have multiple myeloma and other blood cancers

• VIVUS Announces Closing of $11.55 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

  4/3/2020

  VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced the completion of its previously announced registered direct offering of 7,218,750 shares of the Company’s common stock at a purchase price of $1.60 per share for gross proceeds of $11.55 million

• Vivera Pharma CEO Exposes Questionable Practices of Importers of Fraudulent Chinese COVID-19 Tests

  4/3/2020

  Vivera Pharmaceuticals, Inc. a California based pharmaceutical company, is proud to do its part in delivering safe, effective COVID-19 testing

• UroGen Announces Positive Interim Data from Phase 2b Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer

  4/3/2020

  UroGen Pharma Ltd. (Nasdaq:URGN) announced positive interim data analysis of UGN-102 (mitomycin) for intravesical solution in patients with low-grade intermediate risk non-muscle invasive bladder cancer (LG IR-NMIBC)

• Beroni Group Included in List of Commercial Manufacturers and Laboratories Who Have Notified US FDA of Validated Serology Tests for COVID-19

  4/3/2020

  Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an international diversified biopharmaceutical enterprise focused on the research, development, innovation and commercialization of therapies and products for treatment of global diseases, is pleased to announce it has been added to the list of Commercial Manufacturers and Laboratories which have notified the U.S. Food and Drug Administration

• $4 M for MUHC Foundation COVID-19 Emergency Fund - Prominent Montreal families come together to fight the pandemic

  4/3/2020

  As cases of COVID-19 climb steeply and Quebec society grounds to a near halt, with all but essential services closed for weeks, the need to find treatments and ultimately a cure for the novel coronavirus is growing increasingly urgent.

• Leica Biosystems Receives FDA's Enforcement Discretion For Use Of Aperio ImageScope DX Viewing Software For Remote Diagnosis During COVID-19 Emergency

  4/3/2020

  Leica Biosystems, the global leader in pathology workflow solutions, today announced it has received notification from the U.S. Food & Drug Administration (FDA) that its Aperio ImageScope DX Viewer with images acquired on the Aperio AT2 DX Scanner can be used for remote diagnosis under emergency use.

• Apria Is Committed to Supporting Its Patients and Local Communities

  4/3/2020

  Apria Healthcare, one of the nation's largest providers of home healthcare and equipment services, is dedicating its full efforts to address the coronavirus healthcare crisis.

• Essentium Makes 3D Printed Face Mask With Reusable Frame

  4/3/2020

  Essentium, Inc., led by the company's COVID-19 Response Strategy Team, has been investigating how to best mobilize its resources and significant IP in materials and additive manufacturing production to aid in the fight against COVID-19.

• HealthcareSource Partners with Amplifire Healthcare Alliance, Now Distributing Infection Prevention and Control (COVID-19) Essentials Course

  4/3/2020

  HealthcareSource, the leading provider of talent management solutions for the healthcare industry, is partnering with Amplifire, an innovative knowledge engineering and training platform, to distribute its Infection Prevention and Control Essentials – Rapid Refresher course to healthcare organizations across the U.S.

• National Pediatric Cancer Foundation launches "Do 43" to honor pediatric cancer research and the 43 children diagnosed daily

  4/3/2020

  The National Pediatric Cancer Foundation (NPCF) today announced Do 43, a new campaign designed to continue shining a critical light on the 43 children diagnosed every day with cancer

• Novan Receives Verbal Guidance from FDA for SB206 and Announces Sato Program Advancement

  4/3/2020

  Novan, Inc. (“the Company” or “Novan”) (Nasdaq:NOVN) today announced that the Company has conducted its Type C meeting with the U.S. Food and Drug Administration (“FDA”) regarding SB206 for the treatment of molluscum.

• I-Mab Announces IND Clearance from FDA for TJM2 to Treat Cytokine Release Syndrome (CRS) Associated with Severe Coronavirus Disease 19 (COVID-19)

  4/3/2020

  I-Mab (Nasdaq: IMAB) ( the “Company”), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug application (IND) to initiate clinical study for TJM2

• La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) for Named Patient Emergency Use in Patients with Septic Shock Due to COVID-19 at University Hospital Frankfurt in Germany

  4/3/2020

  La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that it is providing GIAPREZA™ (angiotensin II) for named patient emergency use in patients with septic shock due to COVID-19 at University Hospital Frankfurt in Germany.

• Impact of COVID-19 on Pharma and Medical Device Companies in Germany: Industry Experts at Infiniti Research Examine Key Implications

  4/3/2020

  A well-known market intelligence company, Infiniti Research, has partnered with several global companies across industries to help meet their strategic objectives and implement seamless route-to-market strategies through turnkey solutions.

• American Association of Endodontists Publishes 'Characteristics of Endodontic Emergencies During COVID-19 Outbreak in Wuhan'

  4/3/2020

  Research is first descriptive study examining emergency dental patients at epicenter of COVID-19 outbreak

• Insight Helps Vivli Launch COVID-19 Portal

  4/3/2020

  The science community now has free access to a COVID-19 research portal that launched today